AbbVie Stock Will $300: Timing and Risks to Watch
AbbVie’s Q1 2026 results show strong immunology growth even as biosimilar challenges weigh on revenue. Analysts debat...
Analyze both dividend and price returns yearly to evaluate total performance and income potential from index fund investments.
28,655 articlesAbbVie’s Q1 2026 results show strong immunology growth even as biosimilar challenges weigh on revenue. Analysts debat...
New York City's Rent Guidelines Board approved a rent freeze for one-year renewals and, for the first time, two-year ...
US-regulated crypto perps are live, moving from approval to execution as Kalshi launches a multi-asset perpetual futu...
Palo Alto Networks’ stock fell after the latest earnings, as traders weighed a murky near-term outlook against the co...
Australian regulators tighten the screws on social platforms for failing to prevent under-16 accounts, signaling a to...
U.S. manufacturers grow second month in a row in February, but tariff-driven pricing pressures and volatile metal cos...
Tensions around the Strait of Hormuz threaten a key energy route that could ripple through markets and household budg...
A global oil disruption could trigger steep price spikes and broad market volatility as key shipping lanes face disru...
A trio of analyst moves targets Accenture, Thomson Reuters and TELUS, reflecting divergent bets on AI demand, margins...
Intel faces a turning point as AI-driven demand and ramping foundry capacity shape intel corp (intc) stock. Analysts ...
NeoCloud stocks jumped on renewed AI compute optimism, led by IREN and CoreWeave, while Mara posted strong momentum l...
The U.S. Treasury granted a broad license allowing Venezuela's state oil company to sell crude directly to U.S. and g...